Variant · Deletion Cna
SMAD4 LOSS
CI-VAR-00002459Explore in graph →CIViC 564
Curated evidence
Evidence by cancer (3 items)
Grouped by cancer context first, then therapy. The same variant can be sensitizing in one cancer and irrelevant in another — contexts are never merged. 50 items per page; a cancer group may continue on the next page.
- Source
- CIViC — Clinical Interpretation of Variants in Cancer
- Dataset
- CIViC evidence items
- Version
- civic-2026-09-08
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Evidence
- expert curation
- License
- CC0 1.0
- PMID
- 36670111
- Run
- ING-CIVIC-20260908-000001
| Molecular profile | Therapy | Type | Level | Direction · significance | Rating (1–5) | Status | Evidence | Source |
|---|---|---|---|---|---|---|---|---|
| Malignant Pancreatic Neoplasm2 | ||||||||
| BRAF V600E AND ERBB2 Amplification AND SMAD4 LOSS AND TP53 V218E | Bevacizumab + Lapatinib + Trametinib + TrastuzumabCombination | Predictive | C | Supports Sensitivity Response | 3 | submitted | EID11712In this clinical trial, 18 patients with pancreatic cancer were recruited. In this case, the patient (74 y/F) with pancreatic cancer harboring, BRAF V600E, SMAD4 Loss, ERBB2 amplification, and, TP53 V… (full text at CIViC) PMID 36670111 · Shaya et al., 2023 · Open in CIViC | civic |
| SMAD4 LOSS | (prognostic) | Prognostic | B | Supports Poor Outcome | 3 | accepted | EID1412Study employed a rapid autopsy technique on a cohort of 76 patients with pancreatic cancer and explored the status of several genes. 63% (41/65) of carcinomas analyzed showed inactivation of SMAD4 (DP… (full text at CIViC) | |
ClinVar
Clinical significance (0)
ClinVar interpretations are shown as structured records — significance, review status, star rating, conditions — never flattened into one word.
Data not yet available